Immunomedics
Acquired
- Headquarters
- Morris Plains, New Jersey
- Employees
- 201–500
- Founded
- 2004
- Business Model
- B2B
- Website
- immunomedics.com
- Total Funding
- $459.0M
- Valuation
- $21.0BSep 2020
- Last Round
- $459.0M Private EquityMay 2020
About
Immunomedics was a clinical-stage biopharmaceutical company pioneering next-generation antibody-drug conjugate (ADC) technology for the targeted treatment of cancer, including triple-negative breast cancer and other solid tumors. Its lead drug, Trodelvy (sacituzumab govitecan), received FDA approval before the company was acquired by Gilead Sciences for $21 billion in 2020.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account